NYC MedTech Program – December 3rd 2019
Dr. Joann Halpern
Design Thinking: Driving Innovation in Healthcare
Dr. Joann Halpern is the director of the Hasso Plattner Institute, New York and an adjunct professor in the Department of Applied Statistics, Social Science and Humanities at New York University. She was the founding director of the German Center for Research and Innovation (GCRI), which was created as a cornerstone of the German government’s initiative to internationalize science and research. In addition to teaching and administrative assignments at universities in the United States and Germany, Dr. Halpern co-founded Knowledge Transfer Beyond Boundaries, an NGO with projects in Cameroon, Nigeria, and Yemen. She received her B.A. from Dartmouth College, her M.A. from Harvard University, and her Ph.D. from New York University. She is a recipient of the Harvard Award for Distinction in Teaching as well as scholarships and fellowships from the Fulbright Association, German Academic Exchange Service, Robert Bosch Foundation, and the National Endowment for the Humanities. Dr. Halpern serves on the advisory boards of the German Accelerator, Charité Entrepreneurship Summit, Technical University of Dortmund, University Alliance Ruhr, and Virtual Enterprises International.
Medality Medical LLC is an innovative medical technology company pursuing surgical reversal of type 2 diabetes. Leveraging its patented Tissue Liquefaction Technology, the Company has used its FDA-cleared and commercialized HydraSolve™ surgical device/system to selectively remove excess mesenteric visceral fat that has been linked to insulin resistance which is a precursor to type 2 diabetes. Proof-of-concept was demonstrated in a published baboon study that was foundational to receiving FDA IDE, IRB other approvals to undertake a human pilot clinical study to investigate the use of HydraSolve™ to reverse type 2 diabetes. The first patient surgery was recently completed.
Dr. Phillip Chan, MD, Phd.
Dr. Phillip Chan is a co-founder and the Vice Chairman of the Board of Directors of Medality Medical, LLC, a privately-held medical device company pursuing the surgical cure of Type-2 diabetes through the removal of deep mesenteric metabolic fat with its FDA-approved HydraSolve™ advanced lipoplasty system. Dr. Chan is also the Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), where he has led the company through the E.U. approval and commercialization of its flagship product, CytoSorb, as a novel blood purification therapy to control deadly inflammation seen in life-threatening illnesses in the intensive care unit and cardiac surgery. Distributed in 58 countries worldwide, CytoSorb has garnered nearly $22M in trailing 12-month sales. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the largest seed and Series A investors in the New York region and a top 1% performing VC fund for its vintage. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. He received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University.
Fx Biopharma, Inc
Fx Biopharma is working to discover and develop a cancer gene therapy platform, delivering novel anti-cancer payloads, with the use of viral delivery vectors directly into the tumor. The company’s lead asset, a preclinical pan Ras inhibitor discovered at Stanford University, will be initially developed in cancer indications devoid of other therapeutic options, such as pancreatic cancer or glioblastoma.
Daniel Brims, Ph.D.
Founder and CEO
Dr. Brims brings over 10 years of drug development and finance experience to Fx Biopharma. He was a part of Regeneron running their E.coli core facility within the antibody discovery group. He holds a Ph.D. in Chemistry from the University of Washington and was a Postdoctoral Fellow at the Albert Einstein College of Medicine, working in the lab of Stan Nathenson, studying immune checkpoints.
We are honored to have worked with Janet Danisman.
Executive Director | Bavaria U.S Offices for Economic Development LLC / East
Honorary Consul of the Federal Republic of Germany / CT & RI
For the introduction of Bavarian companies that are included in our program book.